| |MAY 20238TOP STORIESEnveric Biosciences, Inc., a bio-technology company, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent appli-cation involving EB-373, the company's new chemical entity (NCE) psilocin pro-drug being developed for the treatment of anxiety disorder.The soon-to-be-issued patent, titled "C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using," contains composition of matter claims for a family of novel psilocin prodrug derivatives, including Enveric's lead product candidate, EB-373. After determining that a patent should be granted based on an application, the USPTO issues a Notice of Allowance.Enveric has also filed additional composition of matter patent applications with the USPTO for psilocin prodrugs, including compositions with crystalline molecular structures. Furthermore, companion Patent Cooperation Treaty (PCT) and non-US national patent applications have been filed to pursue global coverage of the EVM201 and EVM301 Series in target market countries, with the majority of those applications receiving positive International Search Reports (ISR) written opinions under the PCT."The positive decision from the USPTO related to our lead candidate, EB-373, highlights the innovative designs of the psilocin prodrugs being developed as part of our EVM201 Series, as well as differentiations in those designs that enable our molecules to potentially elicit a more rapid onset of action, more controlled therapeutic effect, and reduced gastrointestinal side-effects compared to conventional psilocin prodrugs, such as psilocybin," said Joseph Tucker, "Possessing multilayered IP for our NCE prodrugs is an important value driver for Enveric and a key component of our business strategy as we seek to create a portfolio of novel small-molecule therapeutics for the treatment of mental health disorders." POMedtronic plc, the global leader in healthcare technology, has announced an investment of approximately Rs. 3,000 crore (more than US$ 350 million) to expand the Medtronic Engineering & Innovation Centre (MEIC) in Hyderabad, in a significant step towards the growth of the healthcare technology sector in India.MEIC is Medtronic's largest R&D centre outside of the United States. Medtronic's investment is part of the company's overall global R&D-led innovation and growth strategy. Medtronic supports the Telangana government's efforts to establish Hyderabad as a global centre for healthcare technology research and innovation.Medtronic executives Mike Marinaro, executive vice president and president of surgical, Mani Prakash, vice president of Enterprise R&D, and Divya Prakash Joshi, vice president and MEIC Site Leader, met with Telangana Minister for IT, Industries, Municipal Administration, and Urban Development, KT Rama Rao, in New York, USA, to make the announcement. In attendance were Jayesh Ranjan IAS, principal secretary, industries and commerce department, and Shakthi M Nagappan, CEO, Telangana Lifesciences, Government of Telangana. POENVERIC BIOSCIENCES TO GET US PATENT FOR NOVEL PSILOCIN PRODRUGMEDTRONIC INVESTS RS. 3,000 CRORE TO EXPAND ITS HYDERABAD R&D FACILITY
< Page 7 | Page 9 >